Rationale and perspective of endothelin-1 antagonism in acute heart failure.

Abstract

A role of the potent and long-acting vasoconstrictor peptide endothelin (ET)- I in the pathophysiology of chronic human heart failure has been postulated, based upon indirect evidence such as elevated plasma ET-1 levels and their relationship to the degree of haemodynamic impairment. Acute heart failure shares many features of chronic heart failure, albeit in an exaggerated fashion. As both the mixed ETA/ETB-receptor antagonist bosentan and the selective ETA receptor antagonist BQ 123 acutely improved the haemodynamics of chronic heart failure patients, there seems to be good reason to believe that ET-1 receptor antagonism may also be of benefit in the setting of acute heart failure. However, appropriate trials will have to be performed to document the clinical benefit of such an approach. Finally, the question remains open as to whether mixed ET-1 receptor antagonists like bosentan will prove better, worse or equal to antagonists that block the ETA, receptor only.

• Authors: W Kiowski, G Suetsch, E Oechslin, C Schalcher, H P Brunner-Larocca, O Bertel
• Journal: Journal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 38 Suppl 2 Pg. S53-7 (Nov 2001) ISSN: 0160-2446 [Print] United States
• PMID: 11811379 (Publication Type: Journal Article)

Chemical References

• Antihypertensive Agents
• Endothelin Receptor Antagonists
• Endothelin-1
• Peptides, Cyclic
• Receptor, Endothelin A
• Receptor, Endothelin B
• Sulfonamides
• Bosentan
• cyclo(Trp-Asp-Pro-Val-Leu)

Topics

• Acute Disease
• Animals
• Antihypertensive Agents (therapeutic use)
• Bosentan
• Dogs
• Endothelin Receptor Antagonists
• Endothelin-1 (antagonists & inhibitors, blood)
• Heart Failure (drug therapy, physiopathology)
• Humans
• Peptides, Cyclic (therapeutic use)
• Receptor, Endothelin A
• Receptor, Endothelin B
• Sulfonamides (therapeutic use)